Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk

Atherosclerosis

Volumn 164, Issue 2, 2002, Pages 305-311

  Gonbert, Sophie ^a   Malinsky, Sophie ^a   Sposito, Andrei C ^a   Laouenan, Hervé ^b   Doucet, Chantal ^a   Chapman, M John ^a   Thillet, Joëlle ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PFIZER INC   (United States)

Author keywords

Apo(a) fragments; Atorvastatin; Cardiovascular risk; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A; ATORVASTATIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME;

ADULT; AGED; APOLIPOPROTEINS A; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; PROBABILITY; PYRROLES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0036802128     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00072-2     Document Type: Article

References (32)

1. Boerwinkle E., Leffert C.C., Lin J., Lackner C., Chiesa G., Hobbs H.H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90:1992;52-60.
2. Scanu A.M. Atherothrombogenicity of lipoprotein(a): The debate. Am. J. Cardiol. 82:1998;Q26-Q33.
3. Maher V.M.G., Brown B.G., Marcovina S.M., Hillger L.A., Zhao X.Q., Albers J.J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J. Am. Med. Assoc. 274:1995;1771-1774.
4. Marburger C., Hambrecht R., Niebauer J., et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am. J. Cardiol. 73:1994;742-746.
5. Hiraga T., Okubo M., Kobayashi T., Nakanishi K., Sugimoto T., Murase T. Serum lipoprotein(a) levels differ in different phenotypes of primary hyperlipoproteinemia. Metabolism. 42:1993;1327-1330.
6. Ritter M.M., Geiss H.C., Richter W.O., Schwandt P. Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia. Metabolism. 43:1994;572-578.
7. Gonbert S., Saint-Jore B., Giral P., Doucet C., Chapman J., Thillet J. Molecular analysis of apo(a) fragmentation in polygenic hypercholesterolemia: characterization of a new plasma fragment pattern. Arterioscler. Thromb. Vasc. Biol. 21:2001;1353-1358.
8. Mooser V., Marcovina S.M., White A.L., Hobbs H.H. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J. Clin. Invest. 98:1996;2414-2424.
9. Doucet C., Mooser V., Gonbert S., Raymond F., Chapman J., Jacobs C., Thillet J. Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine [In Process Citation]. J. Am. Soc. Nephrol. 11:2000;507-513.
10. Hoff H.F., Oneil J., Smejkal G.B., Yashiro A. Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions. Chem. Phys. Lipids. 67-8:1994;271-280.
11. Fieseler H.G., Armstrong V.W., Wieland E., Thiery J., Schütz E., Walli A.K., Seidel D. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: result of a 2-year investigation. Clin. Chim. Acta. 204:1991;291-300.
12. Wanner C., Bohler J., Eckardt H.G., Wieland H., Schollmeyer P. Effects of Simvastatin on lipoprotein(a) and lipoprotein composition in patients with nephrotic syndrome. Clin. Nephrol. 41:1994;138-143.
13. Umeda F., Watanabe J., Inoue K., et al. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein(a) in patients with non-insulin dependent diabetes mellitus. Endocrin. Japon. 39:1992;45-50.
14. Hunninghake D.B., Stein E.A., Mellies M.J. Effects of one year of treatment with Pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein-a. J. Clin. Pharmacol. 33:1993;574-580.
15. Group T.S.P.S. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group. Am. J. Cardiol. 71:1993;1408-1414.
16. Dallongeville J., Fruchart J.C., Pfister P., Bard J.M. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). J. Intern. Med. 236:1994;95-101.
17. Leitersdorf E., Eisenberg S., Eliav O., et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor Fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation. 87:1993;35-44.
18. McKenney J.M., McCormick L.S., Weiss S., Koren M., Kafonek S., Black D.M. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am. J. Med. 104:1998;137-143.
19. Sampietro T., Galetta F., Bionda A. Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Cardiovasc. Drug Therapy. 9:1995;785-789.
20. Klausen I.C., Gerdes L.U., Meinertz H., Hansen F.A., Faergeman O. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by Pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur. J. Clin. Invest. 23:1993;240-245.
21. Doucet C., Huby T., Chapman J., Thillet J. Lipoprotein[a] in the chimpanzee - relationship of apo[a] phenotype to elevated plasma Lp[a] levels. J. Lipid Res. 35:1994;263-270.
22. Doucet C., Huby T., Ruiz J., Chapman M.J., Thillet J. Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis. 118:1995;135-143.
23. Haffner S., Orchard T., Stein E., Schmidt D., LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin. Cardiol. 18:1995;261-267.
24. Guo H.C., Chapman M.J., Bruckert E., Farriaux J.P., De Gennes J.L. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype. Atherosclerosis. 31:1991;69-83.
25. Knight B.L. Lp(A) catabolism in hypercholesterolaemic individuals. Chem. Phys. Lipids. 67-8:1994;233-239.
26. Crook M.A., Haq S., Chusney G., Haq M., Tutt P. Acute phase proteins and lipoprotein(A) in patients with severe hypercholesterolaemia and normal subjects. Clin. Chim. Acta. 224:1994;199-201.
27. Slunga L., Johnson O., Dahlen G.H., Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand. J. Clin. Lab. Invest. 52:1992;95-101.
28. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann. Med. 32:2000;164-176.
29. Edelstein C., Shapiro S.D., Klezovitch O., Scanu A.M. MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5: potential relevance to lipoprotein(a) biology. Arterioscler. Thromb. Vasc. Biol. 19:1999;1060-1065.
30. Bellosta S., Bernini F., Ferri N., et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 137:1998;S101-S109.
31. Ikeda U., Shimpo M., Ohki R., Inaba H., Takahashi M., Yamamoto K., Shimada K. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension. 36:2000;325-329.
32. Schulter V., Koolwijk P., Peters E., et al. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21:2001;433-438.